Redemplo Plozasiran Application Scope

Redemplo® (Plozasiran Sodium Injection) is indicated, as an adjunct to a low-fat diet, for reducing triglyceride (TG) levels in adult patients with Familial Chylomicronemia Syndrome (FCS). Treatment should be initiated and supervised by physicians experienced in the management of FCS.

Plozasiran Characteristics

Ingredients: Each prefilled syringe contains 25 mg of plozasiran sodium. The inactive ingredients are sodium chloride and water for injection.
Properties: Redemplo is a sterile, preservative-free, clear to slightly yellow solution for subcutaneous injection.
Packaging Specification: One single-dose prefilled syringe containing 25 mg/0.5 mL.
Storage: Store refrigerated at 2°C–8°C. Do not freeze. Keep in the original carton to protect from light. It may be kept at room temperature (20°C–25°C) for up to 30 days.
Expiry Date: Refer to the expiration date printed on the package.
Executive Standard: Not specified in the approved prescribing information.
Approval Number: Refer to the product package approved by the National Medical Products Administration (NMPA).
Date of Revision: 13 February 2026.
Manufacturer: Developed by Arrowhead Pharmaceuticals, Inc. Marketed in China by Sanofi (China).

Guidelines for the Use of Redemplo

Dosage and Administration:
- Recommended Dose: The recommended dose is 25 mg administered once every 3 months by subcutaneous injection.
- Administration: Redemplo is administered by subcutaneous injection into the abdomen or the front of the thigh. The upper outer arm may be used when the injection is given by a healthcare professional or caregiver.
- Missed Dose: If a dose is missed, administer it as soon as possible and continue dosing every 3 months from the date of the most recent injection.
Adverse Reactions:
- Common Adverse Reactions: The most common adverse reactions include hyperglycemia, headache, nausea, and injection-site reactions.
- Serious Adverse Reactions: No specific serious adverse reactions have been identified in the approved prescribing information.
Contraindications: There are no contraindications listed in the approved prescribing information.
Precautions:
- Use only under the supervision of physicians experienced in treating FCS.
- Continue a strict low-fat diet throughout treatment.
- Safety and efficacy in pediatric patients have not been established.
- Pregnancy and breastfeeding: Use only if the potential benefit justifies the potential risk; consult the full prescribing information.
- Monitor patients according to routine clinical practice.

Plozasiran Interactions

Formal drug-drug interaction studies have not identified clinically significant interactions requiring dose adjustment. Patients should inform healthcare providers of all prescription medicines, over-the-counter medicines, vitamins, and herbal supplements before treatment.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.